Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inidascamine (RL-007) in Cognitive Impairment Associated With Schizophrenia
NCT05686239Phase 2Completed
- Sponsor
- Recognify Life Sciences
- Start
- Dec 2022
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
A Phase 2 trial of inidascamine in schizophrenia, sponsored by Recognify Life Sciences. Started Dec 2022; status: completed.
02
Drugs
inidascamine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05686239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686239.